Robert J. Lefkowitz MD - 30 Apr 2022 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Reporting owner
Role
Director
Signature
/s/ Robert J. Lefkowitz
Issuer context
Issuer symbol
LXRX
Transaction snapshot
Transactions as of
30 Apr 2022
Net transaction value
$0
SEC evidence
Form type
4
Filing time
02 May 2022, 16:15:42 UTC
Next filing
23 May 2022
SEC filing
View on sec.gov

Key filing fact

Robert J. Lefkowitz MD filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 02 May 2022.

Key facts

  • This page summarizes Robert J. Lefkowitz MD's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 02 May 2022, 16:15.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported transactions

LXRX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+4,024
Change %
+15%
Price
$0.000000
Shares after
31,030
Date
30 Apr 2022
Ownership
Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

LXRX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-4,024
Change %
-100%
Price
$0.000000*
Shares after
0
Date
30 Apr 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,024
Exercise price
$0.000000
Footnotes
F1, F2
* indicates a reported price that failed the local validity check.

Explanation of Responses:

Id Content
F1 Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .